Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours
dc.contributor.author | Solano Iturri, Jon Danel | |
dc.contributor.author | Echevarría Orella, Enrique | |
dc.contributor.author | Unda Urzaiz, Jesús Miguel | |
dc.contributor.author | Loizaga Iriarte, Ana | |
dc.contributor.author | Pérez Fernández, Amparo | |
dc.contributor.author | Angulo, Javier C. | |
dc.contributor.author | López Fernández de Villaverde, José Ignacio | |
dc.contributor.author | Larrinaga Embeita, Gorka | |
dc.date.accessioned | 2021-03-02T11:17:03Z | |
dc.date.available | 2021-03-02T11:17:03Z | |
dc.date.issued | 2021-02-10 | |
dc.identifier.citation | Diagnostics 11(2) : (2021) // Article ID 272 | es_ES |
dc.identifier.issn | 2075-4418 | |
dc.identifier.uri | http://hdl.handle.net/10810/50413 | |
dc.description.abstract | (1) Background: Renal cancer is one of the most frequent malignancies in Western countries, with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of reliable biomarkers of tumour progression. (Pro)renin receptor (PRR) is a novel receptor of the renin–angiotensin system (RAS) that has been associated with the development and progression of some solid tumours by RAS-dependent and -independent mechanisms. (2) Methods: In this study, we analysed the immunohistochemical expression of PRR at the centre and border in a series of 83 clear-cell renal cell (CCRCCs), 19 papillary (PRCC) and 7 chromophobe (ChRCC) renal cell carcinomas, and the benign tumour renal oncocytoma (RO, n = 11). (3) Results: PRR is expressed in all the tumour subtypes, with higher mean staining intensity in ChRCCs and ROs. A high expression of PRR at the tumour centre and at the infiltrative front of CCRCC tissues is significantly associated with high grade, tumour diameter, local invasion and stage, and with high mortality risk by UCLA integrated staging system (UISS) scale. (4) Conclusions: These findings indicate that PRR is associated with the development and progression of renal tumours. Its potential as a novel biomarker for RCC diagnosis/prognosis and as a promising therapeutic target should be taken into account in the future. | es_ES |
dc.description.sponsorship | The work was funded by the Basque Government (ELKARTEK KK2018-00090 and KK-2020/00069). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | renal cell carcinoma | es_ES |
dc.subject | (Pro)renin receptor | es_ES |
dc.subject | renin–angiotensin system | es_ES |
dc.subject | prognosis | es_ES |
dc.title | Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2021-02-26T14:40:51Z | |
dc.rights.holder | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/2075-4418/11/2/272/htm | es_ES |
dc.identifier.doi | 10.3390/diagnostics11020272 | |
dc.departamentoes | Fisiología | |
dc.departamentoes | Enfermería | |
dc.departamentoeu | Fisiologia | |
dc.departamentoeu | Erizaintza |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).